Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes an end-to-end solution comprising instruments, consumables, and software analysis. It also offers a proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffer system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. and Weill Cornell Medicine—Qatar have a research collaboration with The Michael J. Fox Foundation to study the connection between the alpha-synuclein (aSyn) protein and Parkinson's disease (PD). Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.